ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
AbstractErbB family members represent important biomarkers and drug targets for modern precision therapy. They have gained considerable importance as paradigms for oncoprotein addiction and personalized medicine. This review summarizes the current understanding of ErbB proteins in cell signalling and cancer and describes the molecular rationale of prominent cases of ErbB oncoprotein addiction in different cancer types. In addition, we have highlighted experimental technologies for the development of innovative cancer cell models that accurately predicted clinical ErbB drug efficacies. In the future, such cancer models might facilitate the identification and validation of physiologically relevant novel forms of oncoprotein and non-oncoprotein addiction or synthetic lethality. The identification of genotype-drug response relationships will further advance personalized oncology and improve drug efficacy in the clinic. Finally, we review the most important drugs targeting ErbB family members that are under investigation in clinical trials or that made their way already into clinical routine. Taken together, the functional characterization of ErbB oncoproteins have significantly increased our knowledge on predictive biomarkers, oncoprotein addiction and patient stratification and treatment. View Full-Text
Share & Cite This Article
Jacobi, N.; Seeboeck, R.; Hofmann, E.; Eger, A. ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers 2017, 9, 33.
Jacobi N, Seeboeck R, Hofmann E, Eger A. ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers. 2017; 9(4):33.Chicago/Turabian Style
Jacobi, Nico; Seeboeck, Rita; Hofmann, Elisabeth; Eger, Andreas. 2017. "ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology." Cancers 9, no. 4: 33.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.